TLSI at a glance
TriSalus Life Sciences, Inc. (TLSI, SEC CIK 1826667) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on September 22, 2026 and Form 4 insider filings as recently as July 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), TriSalus Life Sciences, Inc. (TLSI) reported revenue of $45.2 million (up 53.4% from FY2024) and a net loss of $39.2 million. Diluted EPS was -$1.84.
- As of June 30, 2026, 17 institutional investment managers tracked by SignalX reported holding TriSalus Life Sciences, Inc. (TLSI) shares worth $31.0 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $45.2M
- +53.4% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 17 funds
- $31.0M · +0 vs prior quarter
- Latest 8-K
- Sep 22, 2026
- Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Q2 revenue $11.407M, up 1.7% YoY from $11.213M, primarily PEDD infusion-system sales
- Gross margin 86.8% vs 83.9% YoY, driven by lower cost per TriNav unit
- Sales and marketing $11.416M, up 59.4% YoY; only reportable segment, TriNav product family
- Cash and equivalents $46.3M at June 30, 2026 vs $20.4M December 31, 2025; operating cash use $16.6M
- Management expects continued operating losses; clinical update planned second half 2026 and additional capital may be required
Risk Factors
- No material changes to risk factors from the December 31, 2025 Form 10-K
- Credit agreement amendment filed with OrbiMed, indicating continued financing and debt-related exposure
- No newly disclosed regulatory, legal, operational, competitive, market, liquidity, currency, or concentration risks in provided text
AI summary of the TLSI 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- FDA 510(k) clearance received for TriNav Advance, removing a key U.S. regulatory barrier
- Commercialization expected to commence, creating potential revenue opportunity for TriSalus
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results released for quarter ended June 30, 2026
- Full operating metrics and management commentary contained in Exhibit 99.1
Item 5.07: Submission of Matters to a Vote of Security Holders
- 67.9% shareholder participation, with 41,728,676 shares represented at the annual meeting
- Mary Szela and Gary Gordon reelected as directors through 2029, with approximately 31.4 million votes each
AI summaries of TLSI 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for TLSI
Don't miss the next TLSI filing
- Alerts as it files. A push when TLSI files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut TLSI, by share count.
- Ask anything. An AI agent that reads every TLSI filing and answers with sources.
TLSI alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Patience David | F | Jul 1, 2026 | 14,650 | $4.46 |
| Szela Mary T | A | Jun 30, 2026 | 3,990 | $3.87 |
| Marshak Richard | A | Jun 30, 2026 | 561 | $3.87 |
| Marshall Richard Henry | A | Jun 29, 2026 | 120,000 | - |
| Marshall Richard Henry | A | Jun 29, 2026 | 60,000 | - |
| MATLIN DAVID J | A | May 14, 2026 | 28,201 | - |
| Valle William | A | May 14, 2026 | 28,201 | - |
| MATLIN DAVID J | A | May 14, 2026 | 23,065 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $29.4M | $45.2M |
| Gross Profit | - | $25.3M | $38.2M |
| Operating Income | - | -$36.2M | -$26.9M |
| Net Income | - | -$30.0M | -$39.2M |
| Gross Margin | - | 86.1% | 84.6% |
| Op. Margin | - | -122.9% | -59.7% |
| Net Margin | - | -102.1% | -86.9% |
| Balance Sheet | |||
| Total Assets | $25.7M | $24.0M | $35.3M |
| Equity | - | -$25.9M | -$33.9M |
| ROE | - | 116.0% | 115.8% |
| Per Share | |||
| EPS | - | $-1.31 | $-1.84 |
| Cash Flow | |||
| Operating CF | -$50.0M | -$40.8M | -$18.0M |
| CapEx | - | $345K | $918K |
Source: XBRL data in TriSalus Life Sciences, Inc. (TLSI)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate TLSI share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 17 | $31.0M |
| Q1 2026 | 17 | $17.5M |
| Q4 2025 | 16 | $30.5M |
| Q3 2025 | 14 | $13.0M |
| Q2 2025 | 12 | $11.1M |
| Q1 2025 | 12 | $5.3M |
| Q4 2024 | 6 | $3.1M |
| Q3 2024 | 4 | $623,000 |
- BlackRock+1.16M (+77%)
- Vanguard Capital Management LLC+382.3K (+28%)
- State Street Corp+282.9K (+86%)
- Vanguard Portfolio Management LLC+164.6K (+100%)
- Northern Trust+158.1K (+71%)
- AQR Capital Management+118.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 98 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
TLSI filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Sep 22, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | May 15, 2026 | - | - | |
| 4 | May 15, 2026 | - | - | |
| SC 13G | May 15, 2026 | - | - | |
| 4 | May 15, 2026 | - | - | |
| 4 | May 15, 2026 | - | - | |
| 4 | May 15, 2026 | - | - | |
| 4 | May 15, 2026 | - | - | |
| 8-K | May 14, 2026 | - | Analysis | |
| 10-Q | May 12, 2026 | Mar 31, 2026 | Analysis | |
| SC 13G | May 12, 2026 | - | - | |
| 8-K | May 12, 2026 | - | Analysis | |
| 8-K | Apr 29, 2026 | - | Analysis | - |
| 4 | Apr 20, 2026 | - | - | - |
| 8-K | Apr 7, 2026 | - | Analysis | - |
| 4 | Apr 1, 2026 | - | - | - |
| 4 | Mar 20, 2026 | - | - | - |
| 4 | Mar 20, 2026 | - | - | - |
| 4 | Mar 20, 2026 | - | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
TLSI SEC filings: frequently asked questions
Which institutions hold TLSI stock?
As of June 30, 2026, the largest TriSalus Life Sciences, Inc. (TLSI) holders among the 13F filers tracked by SignalX were BlackRock ($12.1 million), Vanguard Capital Management LLC ($7.9 million), State Street Corp ($2.8 million), Morgan Stanley ($1.8 million), Northern Trust ($1.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was TLSI's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), TriSalus Life Sciences, Inc. (TLSI) reported revenue of $45.2 million (up 53.4% from FY2024) and a net loss of $39.2 million. Diluted EPS was -$1.84. The figures come from the XBRL data in the 10-K.
What did TLSI report in its latest 8-K?
TriSalus Life Sciences, Inc. (TLSI) filed an 8-K on September 22, 2026 reporting Item 8.01 (Other Events). FDA 510(k) clearance received for TriNav Advance, removing a key U.S. regulatory barrier.
What are the latest TLSI SEC filings?
TriSalus Life Sciences, Inc. (TLSI) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on September 22, 2026 and a Form 4 insider filing on July 6, 2026.
What is TLSI's SEC CIK number?
TriSalus Life Sciences, Inc. (TLSI)'s SEC Central Index Key (CIK) is 1826667. EDGAR lists every TLSI filing under that number.
Ask anything about TLSI
The research agent reads TLSI's filings, financials, insider trades and 13F holders, then answers with sources.